~~<i id='AFC2C41884'><strike id='AFC2C41884'><tt id='AFC2C41884'><pre id='AFC2C41884'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

leisure time

entertainment

author：entertainment 2025-09-30 20:47:07 - browse：4525

The Food and Drug Administration said on Friday that it has some safety concerns about an experimental CRISPR-based treatment for sickle cell disease, citing the methods used by its makers to evaluate the risk of inadvertently making unwanted changes to patients’ DNA.

None of the concerns raised by the FDA on Friday, however, suggest the agency is reluctant to approve the treatment, called exa-cel, which is being developed by Vertex Pharmaceuticals and CRISPR Therapeutics.

Exa-cel, given as a one-time infusion, uses CRISPR genome-editing technology to patch up the genetic faults at the root of sickle cell disease.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： State Dept. review finds Biden bears some blame for Afghanistan failures
Next article： Medicare wants to send $9 billion to 340B hospitals

focus

explore

focus

leisure time

hotspot

entertainment

AdobeAgrowingnumberofAItoolsarebeingusedtopredicteverythingfromsepsistostrokes,withthehopeofaccelera

WSS

How doctors and nurses shape Google's AI

Takeaways from AdvaMed, the largest medical devices conference

Tulsa Race Massacre survivors and attorneys respond to dismissal of lawsuit

Bank of America ordered to pay more than $100 million for double charging fees, withholding rewards

Medicare to cover more brain scans related to Alzheimer’s drugs

Pandemic and All Hazards Preparedness Act needs lean update

leisure time

entertainment

focus

Duchenne breakthrough therapy leaves behind pioneering families

Teachers share how revamped forgiveness program helped with their student loans

Medical leaders decry Supreme Court decision on affirmative action

Medicare to cover more brain scans related to Alzheimer’s drugs

BioMarin wins approval for gene therapy to treat hemophilia A

Akero's treatment for NASH falls short in cirrhosis study

Hepatitis C has a cure — but many Americans still lack access to it

Massive project maps cells in human brain in unprecedented detail

Duchenne breakthrough therapy leaves behind pioneering families

Female surgeons have lower rates of long

explore

Judge agrees to delay next hearing in Trump classified documents case

STAT Readout Newsletter: Today in biotech, life science news

Wisconsin governor employs partial veto to fund schools for 4 centuries

Female surgeons have lower rates of long

European regulators recommend Amylyx's ALS drug be rejected

Biden’s NIH nominee is languishing in Congress

focus

leisure time

hotspot

entertainment